cdi-988
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 27, 2023 (NCT05977140)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Replicase polyprotein 1aINHIBITOR
Replicase polyprotein 1a inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07198139 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2025 | Cocrystal Pharma, Inc. |
| NCT05977140 | Phase 1 | Sep 27, 2023 | Cocrystal Pharma Australia Pty Ltd., Cocrystal Pharma, Inc., Nucleus Network Ltd, Scientia Clinical Research Limited Sydney |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cocrystal Pharma, Inc. | For profit | 2 | 2 | 2 | 2023 |
| Cocrystal Pharma Australia Pty Ltd. | For profit | 1 | 0 | 1 | 2023 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2023 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1